COR - NYSE

Cencora, Inc.

COR·NYSE

$263.64

-0.40%

HealthcareMedical - Distribution

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$51.29B

EPS8.0200

P/E Ratio32.87

Earnings Date08/05/2026

76.59B

Assets

14%

3Y+35.0%

5Y+73.0%

10Y+128.0%

74.84B

Total Liabilities

13%

3Y+32.0%

5Y+66.0%

10Y+138.0%

1.75B

Total Equity

122%

3Y+2351.0%

5Y-308.0%

10Y-18.0%

Cencora, Inc. Funding & Solvency Profile

COR · NYSE

Current Assets

Cash & Cash Equivalents4.39B

Net Receivables25.23B

Inventory20.49B

Other Current Assets2.13B

Total Current Assets52 B

Non-Current Assets

Property, Plant & Equipment4.09B

Goodwill & Intangible Assets17.45B

Long-Term Investments0.00

Other Non-Current Assets2.60B

Total Non-Current Assets7 B

Total Assets

76.59B

Financial Health Analysis

Current Ratio

0.90x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Debt-to-Equity Ratio

42.84x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

-5581466000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

68% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Financial stress indicators: Both liquidity and leverage metrics raise concerns. The company may face challenges meeting obligations and should focus on strengthening its balance sheet.

Cencora, Inc. Balance Sheet

COR • NYSE

Cencora, Inc. Balance Sheet	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011	Sep 2010	Sep 2009	Sep 2008	Sep 2007	Sep 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	4.4B	3.2B	2.7B	3.5B	2.5B	4.6B	3.4B	2.5B	2.4B	2.7B	2.2B	1.8B	1.2B	1.1B	1.8B	1.7B	1B	878.1M	640.2M	1.3B
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	467.4M	67.8M
Cash & Short-Term Investments	4.4B	3.2B	2.7B	3.5B	2.5B	4.6B	3.4B	2.5B	2.4B	2.8B	2.2B	1.8B	1.2B	1.1B	1.8B	1.7B	1B	878.1M	1.1B	1.3B
Net Receivables	25.2B	23.9B	20.9B	18.6B	18.4B	14.3B	12.4B	11.3B	10.3B	9.2B	8.2B	6.3B	6.1B	3.8B	3.8B	3.8B	3.9B	3.5B	3.5B	3.4B
Accounts Receivables	25.2B	23.9B	20.9B	18.5B	18.2B	13.8B	12.4B	11.3B	10.3B	9.2B	8.2B	6.3B	6.1B	3.8B	3.8B	3.8B	3.9B	3.5B	3.5B	3.4B
Other Receivables	0.0	88.2M	77.1M	172.6M	221.9M	488.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	20.5B	19B	17.5B	17.1B	15.4B	12.6B	11.1B	11.9B	11.5B	10.7B	9.8B	8.6B	7B	5.5B	5.4B	5.2B	5B	4.2B	4.1B	4.4B
Prepaids	0.0	0.0	0.0	0.0	372.9M	189.3M	157.4M	169.1M	103.4M	210.2M	189M	85M	129.2M	72.4M	86.7M	52.6M	55.1M	55.9M	32.8M	32.1M
Other Current Assets	2.1B	1.7B	1.8B	342.9M	2.1B	1.3B	1.1B	0.0	0.0	0.0	0.0	0.0	0.0	662.9M	225.4M	0.0	0.0	43.7M	0.0	0.0
Total Current Assets	52.2B	47.7B	42.8B	39.6B	38.8B	33.1B	28.1B	25.9B	24.3B	22.9B	20.3B	16.8B	14.4B	11.1B	11.4B	10.7B	10B	8.7B	8.7B	9.2B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.1B	3.3B	3.2B	3.1B	3.2B	1.5B	1.8B	1.9B	1.8B	1.5B	979.3M	899.6M	803.6M	743.7M	672.9M	711.7M	619.2M	552.2M	507M	509.7M
Goodwill	13.7B	9.3B	9.6B	8.5B	9B	6.7B	6.7B	6.7B	6B	6B	4.1B	2.9B	2.9B	2.9B	2.5B	2.5B	2.9B	2.5B	2.6B	2.6B
Intangible Assets	3.8B	4B	4.4B	4.3B	5.3B	1.9B	2.3B	2.9B	2.8B	3B	2B	533.2M	554.7M	580.4M	282.8M	301M	2.1M	338.4M	477.7M	475.1M
Goodwill & Intangible Assets	17.5B	13.3B	14B	12.8B	14.3B	8.6B	9B	9.6B	8.9B	9B	6.1B	3.5B	3.5B	3.5B	2.8B	2.8B	2.9B	2.9B	3.1B	3.1B
Long-Term Investments	0.0	66.6M	63.1M	60.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	208.8M	246.3M	200.7M	237.6M	290.8M	361.6M	0.0	0.0	0.0	0.0	-65.9M	-3.6B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.6B	2.4B	2.3B	756.3M	726.8M	779.9M	269.1M	270.9M	337.7M	295.6M	298.5M	350.7M	221.7M	116.7M	129M	129.4M	140.7M	120.5M	0.0	0.0
Total Non-Current Assets	24.4B	19.4B	19.8B	17B	18.5B	11.2B	11B	11.8B	11B	10.8B	7.4B	4.7B	4.5B	4.4B	3.6B	3.7B	3.6B	3.5B	3.6B	3.6B
Total Assets	76.6B	67.1B	62.6B	56.6B	57.3B	44.3B	39.2B	37.7B	35.3B	33.6B	27.7B	21.5B	18.9B	15.4B	15B	14.4B	13.6B	12.2B	12.3B	12.8B
LIABILITIES
CURRENT LIABILITIES
Total Payables	54.7B	50.9B	45.8B	40.2B	38B	31.7B	28.4B	26.8B	25.4B	23.9B	20.9B	15.6B	13.3B	9.5B	9.2B	8.8B	8.5B	7.3B	7B	6.5B
Accounts Payable	54.7B	50.9B	45.8B	40.2B	38B	31.7B	28.4B	26.8B	25.4B	23.9B	20.9B	15.6B	13.3B	9.5B	9.2B	8.8B	8.5B	7.3B	7B	6.5B
Accrued Expenses	0.0	0.0	0.0	0.0	0.0	1.6B	1.1B	881.2M	1.4B	743.8M	691.8M	561.9M	532.6M	570.2M	410.5M	369M	315.7M	270.8M	370.7M	478.5M
Short Term Debt	371.6M	781.1M	823.8M	1.2B	475.6M	501.3M	139M	151.7M	12.1M	610.2M	0.0	0.0	0.0	0.0	392.1M	422K	1.1M	1.7M	476K	1.6M
Tax Payables	337.6M	291.8M	310.7M	281.1M	281.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	2.7B	2.6B	2.2B	2.1B	2.9B	0.0	0.0	0.0	0.0	0.0	0.0	1.1B	1B	1.2B	881.3M	703.6M	645.7M	568.5M	497.1M	479.8M
Total Current Liabilities	57.8B	54.3B	48.8B	43.5B	41.4B	33.9B	29.6B	27.9B	26.8B	25.3B	21.6B	17.3B	14.9B	11.3B	10.9B	9.9B	9.5B	8.2B	7.9B	7.5B
NON-CURRENT LIABILITIES
Long Term Debt	9B	4.8B	5.1B	5.5B	7.3B	3.6B	4B	4.2B	3.4B	3.6B	3.5B	2B	1.4B	1.4B	972.9M	1.3B	1.2B	1.2B	1.2B	1.1B
Deferred Tax Liabilities (Non-Current)	1.6B	1.6B	1.7B	1.6B	1.7B	686.5M	1.9B	1.8B	2.5B	2.2B	1.9B	241.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	5B	4.5B	5.4B	5B	5.4B	7B	703.4M	762.2M	511.3M	436.5M	331.1M	88.3M	331.7M	325.9M	267.7M	231M	199.7M	152.7M	126M	89.6M
Total Non-Current Liabilities	17B	12B	13.1B	13B	15.4B	11.3B	6.6B	6.8B	6.4B	6.2B	4.4B	2.3B	1.7B	1.7B	1.2B	1.6B	1.4B	1.3B	1.4B	1.2B
Capital Lease Obligations	1.4B	1B	924.2M	864.3M	946.2M	478.1M	187.4M	204.4M	351.6M	276M	4.7M	5.6M	6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	74.8B	66.3B	61.9B	56.5B	56.8B	45.1B	36.2B	34.6B	33.3B	31.5B	27.1B	19.6B	16.6B	13B	12.1B	11.5B	10.9B	9.5B	9.2B	8.6B
SHAREHOLDERS' EQUITY
Treasury Stock	-10.3B	-9.8B	-8.2B	-7B	-6.5B	-6.5B	-6.1B	-5.4B	-4.8B	-4.4B	-4.2B	-2.3B	-1.5B	-1B	-5.2B	-4.4B	-3.9B	-3.4B	-2.8B	-1.4B
Common Stock	3M	3M	2.9M	2.9M	2.9M	2.9M	2.9M	2.8M	2.8M	2.8M	2.8M	2.7M	2.7M	2.6M	5M	4.9M	4.8M	2.4M	2.4M	2.4M
Additional Paid-In Capital	6.2B	6B	5.8B	5.7B	5.5B	5.1B	4.9B	4.7B	4.5B	4.3B	3.7B	2.7B	2.4B	2.3B	4.1B	3.9B	3.7B	3.7B	3.6B	3.5B
Retained Earnings	6.5B	5.4B	4.3B	3B	1.7B	518.3M	4.2B	3.7B	2.4B	2.3B	1.2B	1.6B	1.5B	1.3B	4.1B	3.5B	2.9B	2.5B	2.3B	2.1B
Accumulated Other Comprehensive Income/Loss	-901.4M	-989.1M	-1.4B	-1.8B	-445.4M	-108.8M	-112M	-79.3M	-95.9M	-114.3M	-136.3M	-52M	-35.5M	-32.7M	-50.9M	-42.5M	-46.1M	-16.5M	-5.2M	-15.3M
Total Stockholders' Equity	1.5B	645.9M	522M	-211.6M	223.4M	-1B	2.9B	2.9B	2.1B	2.1B	616.4M	2B	2.3B	2.5B	2.9B	3B	2.7B	2.7B	3.1B	4.1B
Total Equity	1.7B	786.7M	666.3M	71.3M	584.4M	-839.6M	3B	3B	2.1B	2.1B	616.4M	2B	2.3B	2.5B	2.9B	3B	2.7B	2.7B	3.1B	4.1B
Minority Interest	239.1M	140.8M	144.3M	282.8M	361.1M	179.3M	114.3M	117.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	76.6B	67.1B	62.6B	56.6B	57.3B	44.3B	39.2B	37.7B	35.3B	33.6B	28B	21.5B	18.9B	15.4B	15B	14.4B	13.6B	12.2B	12.3B	12.8B
Total Investments	0.0	66.6M	63.1M	60.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	467.4M	67.8M
Total Debt	10.7B	6.7B	6.8B	7.6B	8.8B	4.1B	4.2B	4.3B	3.4B	4.2B	3.5B	2B	1.4B	1.4B	1.4B	1.3B	1.2B	1.2B	1.2B	1.1B
Net Debt	6.4B	3.4B	4.1B	4.1B	6.2B	-478.2M	798.7M	1.8B	1B	1.4B	1.3B	187.1M	165.6M	329.3M	-461M	-314.6M	168.6M	311M	587.6M	-165.8M
Shares Outstanding	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881	193,877,881

SEC Filings

COR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 23, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 18, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 13, 2026	February 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 10, 2026	February 10, 2026	2026	View Filing

Showing 1 to 10 of 586 filings

Related Guides

Blog Categories

Continue your COR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.